Aleniglipron: The Oral GLP-1 Pill With 16% Weight Loss
Aleniglipron is Structure Therapeutics' once-daily oral small-molecule GLP-1 pill. Phase 2 trials show up to 16% weight loss. Here's what the science says.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on July 23, 2026
Our medical review process ensures clinical accuracy and patient safety.
The next front in the obesity-drug race is not another injection — it is a pill. Aleniglipron, Structure Therapeutics' once-daily oral small-molecule GLP-1 receptor agonist, has posted some of the strongest weight-loss numbers ever reported for a swallowable GLP-1 drug. Across its Phase 2 ACCESS program, published in Nature Medicine in June 2026, aleniglipron drove dose-dependent weight loss that rivals injectable therapies while keeping the tolerability profile that patients and prescribers expect from the class.
Evidence: "Once-daily oral aleniglipron produced dose-dependent, placebo-adjusted body-weight reductions of up to 11.3% at week 36, with a safety profile consistent with the GLP-1 receptor agonist class." — ACCESS Phase 2b Trial. Nature Medicine. 2026. DOI: 10.1038/s41591-026-04476-6
What Is Aleniglipron?
Aleniglipron (formerly known by its development code GSBR-1290) is a non-peptide, small-molecule GLP-1 receptor agonist developed by Structure Therapeutics. That chemistry is the whole point. Most GLP-1 medications — injectable semaglutide (Ozempic, Wegovy), injectable tirzepatide (Mounjaro, Zepbound), and the peptide pill oral semaglutide (Rybelsus) — are peptides. Peptides are fragile in the gut, which is why the injectable versions dominate and why the peptide-based oral semaglutide pill needs absorption enhancers and strict fasting rules to work at all.
Aleniglipron is a chemically synthesized small molecule instead. It survives digestion intact, absorbs reliably, and can be taken once daily. It shares this design philosophy with Eli Lilly's orforglipron — the two are the leading candidates in a new generation of oral small-molecule GLP-1 pills aiming to break the injection barrier that keeps many people from ever starting therapy.
How It Works
Structure Therapeutics used structure-based drug design to engineer aleniglipron as a biased agonist — a molecule that preferentially activates the G-protein signaling arm of the GLP-1 receptor rather than the β-arrestin pathway. In theory, this selective activation drives the appetite-suppressing and insulin-releasing effects while limiting the receptor desensitization that can blunt a drug's response over time. It is the same signaling-bias concept behind China's ecnoglutide, applied here to an oral small molecule.
Once it binds the GLP-1 receptor, aleniglipron produces the familiar cascade:
- Appetite suppression through hypothalamic signaling, reducing hunger and "food noise"
- Delayed gastric emptying, which prolongs fullness after meals
- Glucose-dependent insulin secretion, improving blood sugar control
- Reduced glucagon secretion, lowering fasting glucose
Because it acts on the same receptor as injectable GLP-1 drugs, its clinical effects follow the same pattern — weight loss, improved glycemic markers, and cardiometabolic benefits.
Phase 2 Clinical Trial Results
Aleniglipron's evidence comes from the two-part ACCESS program. The core Phase 2b study established efficacy at moderate doses; a follow-on study, ACCESS II, pushed the doses higher.
ACCESS: The Core Phase 2b Study (36 Weeks)
The randomized, double-blind, placebo-controlled Phase 2b ACCESS trial enrolled 230 adults with overweight or obesity and at least one weight-related comorbidity. Participants received once-daily aleniglipron at maintenance doses of 45 mg, 90 mg, or 120 mg, or placebo, for 36 weeks.
Weight loss results at 36 weeks (placebo-adjusted):
| Dose | Placebo-Adjusted Weight Loss |
|---|---|
| 45 mg | −8.2% |
| 90 mg | −9.8% |
| 120 mg | −11.3% |
| Total (120 mg, non-adjusted) | up to −16.2% |
The proportion of responders was striking. On the 120 mg dose, weight reductions of at least 5%, 10%, and 15% occurred in 86%, 70%, and 38% of participants, versus 23%, 7%, and 1% on placebo.
Evidence: "Body-weight loss of ≥5%, ≥10% and ≥15% occurred in 86%, 70% and 38% of participants on 120 mg aleniglipron, versus 23%, 7% and 1% in the placebo arm." — ACCESS Phase 2b Trial. Nature Medicine. 2026. DOI: 10.1038/s41591-026-04476-6
A predefined interim analysis of the open-label extension added two important findings. First, participants kept losing weight after the 36-week double-blind period — through a median of 20 additional weeks — with no apparent weight-loss plateau. Second, starting patients at a lower 2.5 mg dose improved gastrointestinal tolerability during escalation.
ACCESS II: Pushing the Dose Higher (44 Weeks)
ACCESS II tested higher maintenance doses of 180 mg and 240 mg over 44 weeks. The efficacy climbed accordingly.
Weight loss results at 44 weeks (placebo-adjusted):
| Dose | Placebo-Adjusted Weight Loss |
|---|---|
| 180 mg | −16.3% (≈39 lbs) |
| 240 mg | −16.0% (≈37 lbs) |
These figures represent the highest efficacy reported to date for any oral GLP-1 receptor agonist, landing in territory previously reserved for injectables — and again with no sign of the weight curve flattening by the end of the study.
Evidence: "At 44 weeks, placebo-adjusted mean weight loss reached 16.3% at the 180 mg dose, with no evidence of a plateau during the treatment period." — Structure Therapeutics ACCESS II topline data. 2026. DOI: 10.1038/s41591-026-04476-6
Safety and Tolerability
Aleniglipron's adverse-event profile mirrors the well-established GLP-1 class: predominantly mild-to-moderate gastrointestinal effects — nausea, vomiting, and diarrhea — concentrated during dose escalation.
What stands out is how few people quit. Across the ACCESS II program, the overall treatment discontinuation rate was a low 10.4%. Among participants who reached doses of 120 mg or higher between weeks 28 and 44, only one participant (3.7%) discontinued because of an adverse event. The lower 2.5 mg starting dose introduced in the extension study appears to be a meaningful part of that tolerability story, smoothing the early weeks when GI side effects typically peak.
For context on how the class behaves, the pivotal semaglutide trial reported adverse-event-related discontinuation in a single-digit-to-low-double-digit range, and the pattern for oral small molecules has been broadly similar.
How Aleniglipron Compares to Other GLP-1 Drugs
The obesity-drug field is now crowded enough that raw weight-loss percentages only mean something in context. Here is where aleniglipron's Phase 2 numbers sit against the established benchmarks — with the important caveat that cross-trial comparisons are imperfect, since populations, durations, and endpoints differ.
| Drug | Route | Peak Weight Loss | Trial |
|---|---|---|---|
| Aleniglipron | Oral pill | up to 16.3% (placebo-adjusted, 44 wk) | ACCESS II |
| Orforglipron | Oral pill | 12.4% (72 wk) | ATTAIN-1 |
| Oral semaglutide 25 mg | Oral pill | 13.6% (64 wk) | OASIS-4 |
| Semaglutide 2.4 mg | Injection | 14.9% (68 wk) | STEP 1 |
| Tirzepatide 15 mg | Injection | 20.9% (72 wk) | SURMOUNT-1 |
Evidence: "72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists." — Jastreboff AM, et al. New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2511774
Two things jump out. Aleniglipron's ceiling matches or edges past the injectable semaglutide benchmark from STEP 1 and beats both leading oral rivals on headline efficacy — though its trials are shorter, so the comparison is not apples-to-apples. And like every GLP-1 monotherapy that is not tirzepatide, it still trails the dual GIP/GLP-1 receptor agonist on peak weight loss.
Evidence: "Oral semaglutide 25 mg produced a mean body-weight change of −13.6% versus −2.2% with placebo at week 64 in adults with overweight or obesity." — OASIS-4 Trial. New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2500969
The real significance is the format. If a once-daily pill can deliver injectable-tier weight loss, it removes needle aversion, cold-chain storage, and injection-site issues from the equation — and it is far easier to manufacture at the scale that global demand requires.
What Comes Next
Structure Therapeutics has said its Phase 3 program remains on track to begin in the third quarter of 2026. Phase 3 is where the open questions get answered: whether the 16% figure holds up in thousands of patients over a longer horizon, how durable the weight loss is past a year, whether the low discontinuation rate survives at scale, and how aleniglipron performs head-to-head against orforglipron and the injectables. Only late-stage data can settle those, and regulatory approval remains years away.
Key Takeaways
- Aleniglipron is a once-daily, oral, non-peptide small-molecule GLP-1 receptor agonist from Structure Therapeutics (formerly GSBR-1290), engineered as a G-protein-biased agonist.
- Phase 2b ACCESS delivered up to 11.3% placebo-adjusted weight loss at 36 weeks, with 70% of participants on 120 mg losing at least 10% of body weight.
- ACCESS II pushed placebo-adjusted weight loss to 16.3% at 44 weeks on the 180 mg dose — the highest reported for any oral GLP-1 to date, with no weight-loss plateau observed.
- Tolerability was favorable, with an overall 10.4% discontinuation rate and only 3.7% adverse-event-related discontinuation at higher doses; a low 2.5 mg starting dose eased early GI effects.
- A Phase 3 program is slated to start in Q3 2026 — the trials that will determine whether these numbers translate into an approved medication.
Aleniglipron is still an investigational drug, not an approved treatment, and Phase 2 results have a way of shrinking under Phase 3 scrutiny. But its early data make a serious case that the oral GLP-1 pill can compete with the needle on efficacy, not just convenience — and that the second generation of obesity medications may be defined as much by how they are taken as by how much weight they take off.
References
- ACCESS Phase 2b Trial Investigators. Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Nature Medicine. 2026. DOI: 10.1038/s41591-026-04476-6
- Jastreboff AM, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2511774
- OASIS-4 Trial Investigators. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. New England Journal of Medicine. 2025. DOI: 10.1056/NEJMoa2500969
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038
Last updated: 2026-07-23 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.